4 September 2012 - Cyprotex (AIM:CRX), the specialist preclinical contract research organisation (CRO), will be publishing its interim results for the six months ended 30 June 2012 on Thursday 6 September 2012.
Tony Baxter, Chief Executive Officer, and John Dootson, Chief Financial Officer, will present the results to analysts at 9.30am at the offices of FTI Consulting, Holborn Gate, 26 Southampton Buildings, London,
Cyprotex PLC Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel